The live-attenuated TAK-003 vaccine is the second dengue jab to be prequalified by WHO.
WHO said it contains weakened versions of four serotypes of the virus that causes dengue.
Earlier, WHO had prequalified the CYD-TDV vaccine developed by Sanofi Pasteur for dengue.
The UN health body has recommended the use of TAK-003 in children aged 6-16 years in areas with high dengue burden and transmission intensity. As I noted, the vaccine should be administered in a 2-dose schedule with a 3-month interval between doses.“The prequalification of TAK-003 is an important step in expanding Globa’s access to dengue vaccines, as it is now eligible for procurement by UN agencies including UNICEF and PAHO,” said Dr. Rogério Gaspar, WHO Director of Regulation and Prequalification. he said. a statement. He called on more vaccine developers to come forward for evaluation to "ensure that vaccines reach all communities that need them".
Earlier this year, Takeda partnered with Hyderabad-based Biological E to accelerate the manufacturing of TAK-003 in India.
According to the companies, Biological E will expand production capacity to potentially 50 million doses annually.He said it would also accelerate Takeda's efforts to produce 100 million doses annually within a decade.
According to Takeda's phase 3 trial published in Lancet Global Health, TAK-00 provides protection against dengue fever for up to four and a half years (5 months) after vaccination.
Dengue is a vector-borne disease that is spread by the bite of an infected mosquito. Global estimates suggest that there are more than 100–400 million cases of dengue each year and 3.8 billion people live in dengue-endemic countries, the majority of which are in Asia, Africa and the Americas.
WHO said it contains weakened versions of four serotypes of the virus that causes dengue.
Earlier, WHO had prequalified the CYD-TDV vaccine developed by Sanofi Pasteur for dengue.
The UN health body has recommended the use of TAK-003 in children aged 6-16 years in areas with high dengue burden and transmission intensity. As I noted, the vaccine should be administered in a 2-dose schedule with a 3-month interval between doses.“The prequalification of TAK-003 is an important step in expanding Globa’s access to dengue vaccines, as it is now eligible for procurement by UN agencies including UNICEF and PAHO,” said Dr. Rogério Gaspar, WHO Director of Regulation and Prequalification. he said. a statement. He called on more vaccine developers to come forward for evaluation to "ensure that vaccines reach all communities that need them".
Earlier this year, Takeda partnered with Hyderabad-based Biological E to accelerate the manufacturing of TAK-003 in India.
According to the companies, Biological E will expand production capacity to potentially 50 million doses annually.He said it would also accelerate Takeda's efforts to produce 100 million doses annually within a decade.
According to Takeda's phase 3 trial published in Lancet Global Health, TAK-00 provides protection against dengue fever for up to four and a half years (5 months) after vaccination.
Dengue is a vector-borne disease that is spread by the bite of an infected mosquito. Global estimates suggest that there are more than 100–400 million cases of dengue each year and 3.8 billion people live in dengue-endemic countries, the majority of which are in Asia, Africa and the Americas.
